Molecular Dysregulation in Fuchs Corneal Endothelial Dystrophy

Fuchs内皮性角膜营养不良(FECD)是一种40岁以上患者4%的致盲性疾病。 美国。这种情况是无法治愈的。角膜移植是目前最常用的治疗方法。 随着人口老龄化，供体组织日益稀缺。此外，由于移植失败， 移植排斥反应发生在10-25%的角膜移植手术中。这份提案的重点是确定 以往对FECD中的分子信号通路研究较少。圆满完成了特定的 这项提案中的目的可以导致FECD的替代疗法。

Fuchs Endothelial Corneal Dystrophy (FECD) is a blinding disease that affects 4% over the age of 40 in the United States. There is no cure for this condition. Corneal tranplantation is the prevalent treatment. With the aging population, there is increasing scarcity of donor tissues. In addition, tranplant failures due to graft rejections occur in 10-25% of corneal transplantations. This proposal focuses on identifying previously understudied molecular signaling pathways in FECD. Successful completion of the specific aims in this proposal can lead to alternative therapies for FECD.